← Back to Search

Peer Mentorship for Sickle Cell Disease

N/A
Waitlist Available
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged 12-18 years old
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will assess the feasibility and preliminary effectiveness of peer mentorship for youth with sickle cell disease.

Who is the study for?
This trial is for English-speaking youths aged 12-18 with Sickle Cell Disease who have internet access and can use Skype. They should be diagnosed by a hematologist and willing to complete online measures. Those with major illnesses or cognitive impairments, or in other peer support programs cannot join.Check my eligibility
What is being tested?
The iPeer2Peer program pairs young SCD patients with mentors who manage their condition well. Over 15 weeks, the intervention group will have up to ten calls with their mentor, while the control group waits for a mentor. The study aims to see if this is doable and how it affects health outcomes.See study design
What are the potential side effects?
Since this trial involves mentorship rather than medication, there are no direct medical side effects expected. However, participants may experience emotional or social discomfort during interactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are between the ages of 12 and 18.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acceptability of iPeer2Peer SCD intervention
Rates of completion of mentor-mentee calls
Recruitment Rate
+1 more
Secondary outcome measures
PROMIS Pain Interference - 8a
Anxiety
PROMIS depressive symptoms - 8a
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: iPeer2Peer MentorshipExperimental Treatment1 Intervention
In addition to standard care, participants in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modelling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with SCD aged 19-25 who have learned to function successfully with their condition). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
Group II: Waitlist Control GroupActive Control1 Intervention
The control group participants will receive standard care and will be on a waitlist to receive the iPeer2Peer program until 15 weeks after completing their baseline questionnaires.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
iPeer2Peer Mentorship
2017
N/A
~170

Find a Location

Who is running the clinical trial?

Connecticut Children's Medical CenterOTHER
71 Previous Clinical Trials
31,486 Total Patients Enrolled
Royal University Hospital FoundationOTHER
22 Previous Clinical Trials
7,520 Total Patients Enrolled
The Hospital for Sick ChildrenLead Sponsor
682 Previous Clinical Trials
6,945,306 Total Patients Enrolled

Media Library

iPeer2Peer Mentorship Clinical Trial Eligibility Overview. Trial Name: NCT03989986 — N/A
Sickle Cell Disease Research Study Groups: Waitlist Control Group, iPeer2Peer Mentorship
Sickle Cell Disease Clinical Trial 2023: iPeer2Peer Mentorship Highlights & Side Effects. Trial Name: NCT03989986 — N/A
iPeer2Peer Mentorship 2023 Treatment Timeline for Medical Study. Trial Name: NCT03989986 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Mar 2025